All In Biotech

Investigational drug · Phase 3

Leuprorelin acetate

Also called: Leuprolide Open Label, DKF-MA102

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

2 still active

All registered trials

359

Any phase or sponsor naming "Leuprorelin acetate"

First trial start

2014

Dec 17, 2014

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Leuprorelin acetate", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Hormone Sensitive Prostate Cancer
  • Prostate Cancer
  • Cancer of the Prostate
  • Endometriosis
  • Advanced Prostate Cancer

Approved drugs for the same conditions: Prostate cancer · Endometriosis · Oncology · Kidney and urology · Endocrinology and women's health

Largest trials

Live from ClinicalTrials.gov: studies naming "Leuprorelin acetate" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 325 on PubMed

Also in development for Hormone Sensitive Prostate Cancer

  • MevrometostatPF-06821497Phase 33 trials

    Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.